Substance Use Disorder Treatment Approach

Introduction to Substance Use Disorder Treatment

• The American College of Physicians recommends that the most effective treatment for substance use disorder combines pharmacotherapy with evidence-based behavioral therapy, while actively incorporating family members through couples/family therapy and mutual help groups, demonstrating superior outcomes compared to pharmacotherapy alone 1

Substance-Specific Pharmacotherapy Selection

• The American Academy of Family Physicians suggests that office-based buprenorphine is safe and effective and represents first-line medication-assisted treatment for opioid use disorder, supported by Cochrane reviews and multiple randomized controlled trials 2
• The American College of Physicians recommends methadone and naltrexone as alternative evidence-based options for opioid dependence 3, 1
• The American College of Physicians recommends naltrexone 50 mg daily for patients with alcohol use disorder without liver disease 1
• The American College of Physicians recommends acamprosate 666 mg three times daily for patients with alcohol use disorder and liver disease due to no hepatotoxicity risk 1
• The American Academy of Family Physicians states that no pharmacotherapy can be recommended for stimulant dependence in primary care settings despite continued research efforts 4

Evidence-Based Behavioral Interventions

• The American Academy of Family Physicians recommends cognitive-behavioral therapy, motivational enhancement therapy, and contingency management as evidence-based behavioral therapies for substance use disorder 2, 3, 1
• The American College of Physicians suggests that brief interventions using the FRAMES model are effective for hazardous drinkers 1

Family and Social Support Integration

• The American College of Physicians recommends implementing couples/family therapy as part of the treatment plan for substance use disorder 1
• The American College of Physicians suggests that family members should be directed to appropriate mutual help groups such as Al-Anon to address their own responses to the substance use disorder 1

Mutual Help and Peer Support

• The American Academy of Family Physicians recommends encouraging engagement with peer-led groups such as Alcoholics Anonymous, Narcotics Anonymous, SMART Recovery, or Rational Recovery for substance use disorder treatment 4, 5

Treatment Setting Selection Algorithm

• The American Academy of Family Physicians suggests that outpatient treatment is appropriate for patients with relatively stable and safe living environments, while residential treatment is indicated for patients who need a stable and safe living environment 6, 4

Co-occurring Mental Health Disorders

• The American Academy of Family Physicians recommends screening all patients with substance use disorders for mental health conditions, which are significantly more common in this population 6, 2
• The American College of Physicians suggests that integrated treatment for co-occurring disorders demonstrates favorable outcomes 7, 1

Treatment Duration and Monitoring

• The American College of Physicians recommends that optimal pharmacotherapy duration is typically 3-6 months, and regular follow-up and reevaluation are essential even for patients with substance abuse 1, 2

Intimate Partner Violence Screening

• The American Academy of Family Physicians recommends screening all patients with substance use disorders for intimate partner violence, which exceeds 50% in some settings 6, 2

Evidence‑Based Recommendations for Substance‑Use‑Disorder Treatment (Oxytocin Excluded)

Guideline Recommendations

• Major addiction‑medicine guidelines (e.g., those from the American Society of Addiction Medicine) do not list intranasal oxytocin among recommended treatments, focusing instead on established pharmacotherapies combined with behavioral interventions. 8
• The American College of Physicians’ clinical practice guidelines identify methadone, buprenorphine, and naltrexone for opioid‑use disorder; naltrexone and acamprosate for alcohol‑use disorder; and nicotine‑replacement therapy, bupropion, or varenicline for tobacco‑use disorder, with no mention of oxytocin. 9
• The American Academy of Child and Adolescent Psychiatry’s 2025 adolescent‑SUD guideline provides a comprehensive pharmacotherapy list but does not include oxytocin. [10][11]

Pharmacotherapy (Substance‑Specific)

• Opioid‑use disorder: Buprenorphine (first‑line), methadone, or naltrexone should be prescribed together with cognitive‑behavioral therapy or contingency management. (Evidence: guideline consensus) 8
• Alcohol‑use disorder: Naltrexone 50 mg daily (when liver disease is absent) or acamprosate 666 mg three times daily (when liver disease is present). (Evidence: guideline consensus) 8
• Tobacco‑use disorder: Nicotine‑replacement therapy, bupropion, or varenicline are the evidence‑based pharmacologic options. (Evidence: strong, guideline‑based) 9
• Stimulant or cannabis‑use disorders: No pharmacologic agents are currently recommended; treatment relies on behavioral therapy alone. (Evidence: guideline consensus)

Behavioral Interventions (Core Components)

• Cognitive‑behavioral therapy, motivational‑enhancement therapy, and contingency management each have strong supporting evidence for improving SUD outcomes. [10][11]
• Family‑based services and peer‑support groups (e.g., AA, NA, SMART Recovery) should be integrated into the overall treatment plan. (Evidence: strong guideline recommendation) 11

Integrated Treatment Model

• Combining FDA‑approved medication with evidence‑based psychotherapy yields significantly better outcomes than usual care alone, with reported effect sizes of 0.18–0.28. (Evidence: moderate‑quality randomized trials) 8
• Pharmacotherapy alone is insufficient; it must be paired with structured behavioral therapy rather than nonspecific counseling. (Evidence: guideline‑based) 8

Clinical Algorithm Highlights (Guideline‑Based Steps)

All cited facts are drawn from major clinical practice guidelines and high‑quality evidence syntheses, confirming that intranasal oxytocin is *not* an evidence‑based option for substance‑use‑disorder treatment at this time.